Daxor Corporation (NYSEAMERICAN: DXR) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced the presentation of research that shined a positive lite on its work. Of course, this led to excitement among investors, sending the stock on a tear for the top. Today, we’ll talk about the research, what we’re seeing from the stock, and what we’ll be watching for with regard to DXR ahead.
DXR Flies On Presentation Of New Research
As mentioned above, Daxor Corporation is having an overwhelmingly strong start to today’s trading session after announcing the presentation of new research highlighting the significant benefits to patient outcomes through individualization of care guided by blood volume analysis (BVA).
In the release, DXR said that the study was conducted by John E. Strobeck, MD, PhD and Wayne L. Miller, MD, PhD, of the Mayo Clinic. This study was brought up in an American College of Cardiology 2018 Scientific session titled “Cardiotoxicity, Cardiomyophathies and Heart Failure Readmissions”. In a statement, Michael Feldschuh, CEO at DXR, had the following to offer:
The pioneering study confirms that Daxor’s rapid non-invasive diagnostic can be essential to improving outcomes and the related economic costs of hospitalized heart failure. Heart failure is one of the greatest challenges our healthcare system faces – it affects over six million Americans and is responsible for one in nine deaths. Mortality rates for heart failure have been rising and the costs to our system already exceed 30 billion dollars per year. We expect the urgent need for an effective solution will lead to increased interest in our technology and further confirmatory studies.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that it’s important to keep a close eye on the news. After all, the news moves the market. In this particular case, the news released by Daxor proved to be overwhelmingly positive. So, it’s no surprise to see that the stock is making a run for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:37), DXR is trading at $7.39 per share after a gain of $2.39 per share or 47.80% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on DXR. In particular, we’re interested in following the story surrounding the company’s diagnostics tools and excited to see the growth in the company ahead. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!